Archive | Hot Mandates RSS feed for this section

Hot Life Science Investor Mandate 2: Family Office Seeks CRO’s for Allocation – January 8, 2013

7 Jan

A family office in the Midwestern United States is currently seeking to invest in, acquire or recapitalize small- to middle-market businesses. The firm is a non-traditional private equity fund in that the managers of the fund provide all of its capital. Therefore, there are no hard fund investment periods, and they are free to hold and operate portfolio companies with a very long-term perspective if required. The firm operates on an opportunistic basis and makes allocations on a case-by-case basis. They will typically invest into the tens of millions in a potential issuer. Within the life sciences and healthcare space, the partnership seeks contract manufacturing and service provider firms; they are especially interested at this time in service providers such as CRO’s and CMO’s.

Tags: , , ,

Hot Life Science Investor Mandate 3: PE Group Targets Biotech Therapeutics, Medtech – January 8, 2013

7 Jan
A private equity group headquartered in the Western United States is looking for new opportunities in the life sciences space, and although it has no set time frame to make allocations, the firm would invest in a company within the next six months if a compelling opportunity were identified. The firm’s equity investments can range anywhere from $1-25 million.
The firm is most interested in the biotech therapeutics sector, as well as the medical technology space. In terms of companies in the medtech space, they are most interested in firms producing optical devices and active implantable devices. In the biotech therapeutics space, the firm is looking for firms developing drugs targeting neurological disorders of all kinds. They also have a particular interest in companies that are developing therapeutics targeting orphan diseases.

The firm will invest in both pre-revenue companies, as well as companies that have products that are already on the market. The group has a venture capital approach to investing in pre-revenue companies, and for those that have products on the market, it has more of a growth equity approach.

Tags: , , ,

Newer Entries →